medical risk factors

  • 文章类型: Case Reports
    背景:侵袭性曲霉病是由曲霉属引起的真菌感染,通常对免疫功能低下的个体构成危及生命的风险。虽然在有免疫能力的宿主中很少发生,最近的病例报告记录了尸检期间一名免疫功能正常的患者的暴发性肺曲霉病。这里,我们介绍了一个有免疫能力的女性的侵袭性曲霉病,表现为播散性病变。
    方法:2022年3月,一位29岁的亚裔女性到我院就诊,报告胸痛和呼吸急促持续两个月。经检查,她看起来又瘦又不舒服,否则没有明显的异常。X线影像学检查显示她的左肺病变不明确。随后进行支气管镜检查和灌洗,随后开始经验性抗生素治疗。灌洗结果为革兰氏染色阴性,文化,和ABB的ZN染色,但在真菌涂片上发现了许多纵隔菌丝。组织病理学检查提示慢性肉芽肿性炎症伴间隔真菌菌丝,表明曲霉病。随后培养证实了曲霉属物种,提示开始伏立康唑治疗。值得注意的是,患者表现出显著的改善,在短时间内观察到体重增加和食欲恢复。治疗2个月内,她的症状消失了,她恢复正常的日常活动.
    结论:该病例强调了在表现为肺部播散性结节性病变的免疫功能正常个体中对曲霉病的诊断,纵隔,和腹部。临床医生应保持高度怀疑曲霉菌病的指标,如有未解决的肺炎和播散性结节性病变,即使是缺乏传统诱发因素的患者。
    BACKGROUND: Invasive Aspergillosis is a fungal infection caused by Aspergillus species, typically posing life-threatening risks to immunocompromised individuals. While occurrences in immunocompetent hosts are rare, a recent case report documented fulminant pulmonary aspergillosis in an immunocompetent patient during autopsy. Here, we present a case of invasive aspergillosis in an immunocompetent woman, manifesting with disseminated lesions.
    METHODS: A 29-year-old Asian woman presented to our hospital in March 2022, reporting chest pain and shortness of breath persisting for two months. Upon examination, she appeared thin and unwell, with no notable abnormalities otherwise. Radiographic imaging revealed an ill-defined lesion in her left lung. Subsequent bronchoscopy and lavage were performed, followed by initiation of empirical antibiotic therapy. Lavage results were negative for gram staining, culture, and ZN staining for AFB, but revealed numerous septate hyphae on fungal smear. Histopathological examination indicated chronic granulomatous inflammation with septal fungal hyphae, indicative of aspergillosis. Subsequent culture confirmed Aspergillus species, prompting initiation of voriconazole therapy. Remarkably, the patient exhibited significant improvement, with weight gain and restored appetite observed within a short period. Within 2 months of treatment, her symptoms resolved, and she resumed near-normal daily activities.
    CONCLUSIONS: This case highlights the diagnosis of aspergillosis in an immunocompetent individual presenting with disseminated nodular lesions across the lungs, mediastinum, and abdomen. Clinicians should maintain a high index of suspicion for aspergillosis in cases of non-resolving pneumonia and disseminated nodular lesions, even in patients lacking traditional predisposing factors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    (1)背景:更年期是女性生活中的重要事件,可能有助于CVD的发展,这与心血管风险状况的变化有关,代谢健康的标志,和亚临床动脉粥样硬化。这项研究的目的是评估绝经与心血管疾病危险因素和心脏代谢疾病亚临床标志物的关系。(2)方法:本研究纳入了235名来自普通人群的处于不同绝经阶段的妇女。本研究使用的方法是:诊断调查,人体测量(WC,高度,BMI,WHtR),血压测量,静脉血的生化分析(血脂,葡萄糖,胰岛素,HbA1c),和CVD风险评估(ASCVD风险计算器,POL-SCORE,SCORE-2).(3)结果:绝大多数受访者心血管风险较低,无论用于测量CVD风险的量表如何。绝经年龄不是CVD的独立危险因素。在模型1中,发现绝经年龄和绝经以来的时间是增加CVD风险的因素(OR分别为1.186和1.267)。在模型2和模型3中,更年期症状的严重程度不是CVD的危险因素。模型3和4表明,患有代谢综合征(MetS)的女性患CVD的风险明显更高。在模型5中,以MetS为独立因子的CVD比值比为13.812。(4)结论:更年期使女性患CVD的风险增加,而MetS的风险明显更高。
    (1) Background: Menopause is an important event in women\'s lives, possibly contributing to the development of CVD, which is associated with changes in the cardiovascular risk profile, markers of metabolic health, and subclinical atherosclerosis. The aim of this study was to assess the association of menopause with CVD risk factors and subclinical markers of cardiometabolic disease. (2) Methods: The study involved 235 women from the general population at different stages of menopause. The methods used in this study were: diagnostic survey, anthropometric measurement (WC, height, BMI, WHtR), blood pressure measurement, biochemical analysis of venous blood (lipid profile, glucose, insulin, HbA1c), and CVD risk assessment (ASCVD Risk Calculator, POL-SCORE, SCORE-2). (3) Results: The vast majority of respondents had low cardiovascular risk, irrespective of the scale used for measuring the risk of CVD. The age at menopause was not an independent risk factor for CVD. In Model 1, the age at menopause and the time since menopause were found to be factors that increased CVD risk (OR = 1.186 and 1.267, respectively). In Models 2 and 3, the severity of menopausal symptoms was not a risk factor for CVD. Models 3 and 4 demonstrated that women with metabolic syndrome (MetS) were at a significantly higher risk of CVD. In model 5, the odds ratio of CVD with MetS as a standalone factor was 13.812. (4) Conclusions: Menopause predisposes women to an increased risk and MetS to a significantly higher risk of CVD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    COVID-19及其变种的迅速传播摧毁了世界各地的社区,随着高传染性Omicron变种在2021年底成为该病毒的主要毒株,对新变种及其前身之间的差异进行表征和理解的必要性已成为公共卫生当局日益重视的问题。自大流行的早期阶段以来,人工智能在分析COVID-19的各个方面发挥了重要作用。这项研究提出了使用人工智能,特别是XGBoost模型,量化各种医疗风险因素(或“人群特征”)对患者结果导致住院的可能性的影响,入住ICU,或死亡。在Delta和OmicronCOVID-19变体之间比较结果。结果表明,年龄较大和未接种疫苗的患者状态最一致地对应于所有三种情况的最显著的人群特征(住院,ICU,death).确定了每个变异结果情景的前15个特征,其中最常见的包括糖尿病,心血管疾病,慢性肾病,肺炎并发症作为导致严重疾病结局的重要人群特征。Delta/Hoshitalization模型返回了接收器工作特性(AUROC)下区域的最高性能度量分数,F1和回忆,而Omicron/ICU和Omicron/住院具有最高的准确度和精确度值,分别。在大多数情况下(只有两个例外),召回率高于0.60,这表明假阳性的总数通常被最小化(占理论上需要医疗护理的人的更多)。
    The rapid spread of COVID-19 and its variants have devastated communities worldwide, and as the highly transmissible Omicron variant becomes the dominant strain of the virus in late 2021, the need to characterize and understand the difference between the new variant and its predecessors has been an increasing priority for public health authorities. Artificial Intelligence has played a significant role in the analysis of various facets of COVID-19 since the early stages of the pandemic. This study proposes the use of AI, specifically an XGBoost model, to quantify the impact of various medical risk factors (or \"population features\") on the possibility of a patient outcome resulting in hospitalization, ICU admission, or death. The results are compared between the Delta and Omicron COVID-19 variants. Results indicated that older age and an unvaccinated patient status most consistently correspond as the most significant population features contributing to all three scenarios (hospitalization, ICU, death). The top 15 features for each variant-outcome scenario were determined, which most frequently included diabetes, cardiovascular disease, chronic kidney disease, and complications of pneumonia as highly significant population features contributing to serious illness outcomes. The Delta/Hospitalization model returned the highest performance metric scores for the area under the receiver operating characteristic (AUROC), F1, and Recall, while Omicron/ICU and Omicron/Hospitalization had the highest accuracy and precision values, respectively. The recall was found to be above 0.60 in most cases (with only two exceptions), indicating that the total number of false positives was generally minimized (accounting for more of the people who would theoretically require medical care).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    电惊厥疗法(ECT)用于治疗严重的精神疾病,并与严重抑郁症患者的自杀风险和全因死亡率降低有关。我们调查了ECT后不久发生的死亡原因,并确定了医学死亡原因的潜在危险因素。
    2012年至2018年接受ECT治疗的患者被纳入这项基于瑞典注册的研究。使用多变量二元逻辑回归计算协变量的比值比,以确定30天死亡率的潜在预测因子。
    在20,225名患者中,93例(0.46%)死于自杀,123例(0.61%)死于医疗原因。心血管疾病是最常见的医学死亡原因(n=49,40%)。年纪大了,Charlson合并症指数为1或以上,心房颤动,肾病,反流病,痴呆症,和癌症与医疗原因导致的死亡风险增加有关。
    基于注册数据的现实生活中的观察性研究可能显示出关联,但不能确定因果关系。如果有医疗记录,我们就能更好地确定死亡是否是由ECT引起的,麻醉,预先存在的医疗条件,或者精神障碍。
    ECT似乎是一种低风险的医疗程序。患有严重躯体疾病的老年人死亡风险最高,应考虑采取额外措施,以在ECT前检查期间优化其医疗健康,在ECT期间和之后。
    Electroconvulsive therapy (ECT) is used to treat severe psychiatric disorders and is associated with reduced risk of suicide and all-cause mortality in patients with severe depression. We investigated the causes of death occurring shortly after ECT and identified potential risk factors for medical causes of death.
    Patients treated with ECT between 2012 and 2018 were included in this Swedish register-based study. Multivariate binary logistic regression was used to calculate odds ratios for covariates to determine potential predictors of 30-day mortality.
    Of the 20,225 included patients, 93 (0.46 %) died of suicide and 123 (0.61 %) died of medical causes after ECT. Cardiovascular disease was the most common medical cause of death (n = 49, 40 %). An older age, a Charlson Comorbidity Index of 1 or more, atrial fibrillation, kidney disease, reflux disease, dementia, and cancer were associated with increased risk of death by medical causes.
    Real-life observational studies based on registry data may demonstrate associations, but cannot determine causality. If medical records had been available, we would be better able to determine if deaths were due to the ECT, anesthesia, pre-existing medical conditions, or the mental disorder.
    ECT appears to be a low-risk medical procedure. Older individuals with severe somatic diseases have the highest risk of death and extra measures should be considered to optimize their medical health during the pre-ECT workup, and during and after ECT.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:在参与者信息传单(PILs)中共享有关试验干预潜在危害的信息的方式差异很大,并且可能导致主观的“nocebo”危害。这项研究旨在制定原则,以改善有关PIL中潜在的试验干预益处和危害的信息组成,从而减少变异性和可避免的危害。
    方法:我们进行了两轮修改的在线Delphi调查,随后举行协商一致会议。对于第一轮调查,27个声明是根据以前的研究和英国的相关指导制定的,美国和世界卫生组织。与会者包括以下每个利益相关者团体的成员:患者和公众代表,研究伦理委员会成员,行业代表,医学法律专家,心理学家和审判经理。要求每个参与者以9分的李克特量表对每个陈述的同意或不同意程度进行评分。在第二轮中,参与者被邀请在审查第一轮的结果后重新评估他们的评级。最后,每个利益相关者小组的两名成员参加了一次会议,以确认达成一致的声明。
    结果:150名参与者完成了第1轮,201名参与者完成了第2轮。在第一轮中,就16项声明达成了共识。在第二轮中,达成了另外三项声明的共识。协商一致会议确认了调查结果,并合并了声明。这个过程产生了七个原则:(1)应该列出给定干预的所有潜在危害,(2)所有潜在的危害应分为严重和不严重,(3)必须明确,并非所有潜在的危害都是已知的,(4)应列出所有潜在的利益,(5)所有潜在的好处和危害需要与如果参与者没有参加试验会发生什么进行比较,(6)适当时,应添加适当的视觉表示;(7)有关潜在利益和危害的信息不应分开一页或多页。
    结论:我们改进的Delphi过程成功地产生了七个原则,这些原则可以并且应该被用于指导如何在关于潜在试验益处和危害的信息传单中向患者传达信息。
    BACKGROUND: The way information about potential harms of trial intervention is shared within participant information leaflets (PILs) varies widely and can cause subjective \'nocebo\' harms. This study aimed to develop principles to improve the composition of information about potential trial intervention benefits and harms within PILs so that variability and avoidable harms are reduced.
    METHODS: We conducted a two-round modified online Delphi survey, followed by a consensus meeting. For the first round of the survey, 27 statements were developed based on previous research and relevant guidance from the UK, the USA and the World Health Organization. Participants included members from each of the following stakeholder groups: patient and public representatives, research ethics committee members, industry representatives, medico-legal experts, psychologists and trial managers. Each participant was asked to rate their degree of agreement or disagreement with each statement on a 9-point Likert scale. In the second round, participants were invited to reappraise their ratings after reviewing the results of the first round. Finally, two members from each stakeholder group participated in a meeting to confirm those statements for which there was agreement.
    RESULTS: Two hundred and fifty participants completed round 1, and 201 participants completed round 2. In round 1, consensus was reached for 16 statements. In round 2, consensus was reached for an additional three statements. The consensus meeting confirmed the survey results and consolidated the statements. This process resulted in seven principles: (1) all potential harms of a given intervention should be listed, (2) all potential harms should be separated into serious and less serious, (3) it must be made explicit that not all potential harms are known, (4) all potential benefits should be listed, (5) all potential benefits and harms need to be compared with what would happen if the participant did not take part in the trial, (6) suitable visual representations should be added where appropriate and (7) information regarding potential benefits and harms should not be presented apart by one or more pages.
    CONCLUSIONS: Our modified Delphi process successfully generated seven principles that can and should be used to guide how information is conveyed to patients in information leaflets regarding potential trial benefits and harms.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Editorial
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Residual shunt is observed in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term influence on stroke recurrence currently is unknown.
    To investigate the association of residual shunt after PFO closure with the incidence of recurrent stroke and transient ischemic attack (TIA).
    Prospective cohort study comparing stroke or TIA recurrence in patients with and without residual shunt after PFO closure.
    Single hospital center.
    1078 consecutive patients (mean age, 49.3 years) with PFO-attributable cryptogenic stroke who were undergoing percutaneous PFO closure were followed for up to 11 years.
    Residual shunt was evaluated by transthoracic echocardiography with saline contrast. Primary outcome was a composite of the first recurrent ischemic stroke or TIA after PFO closure.
    Compared with complete closure, the presence of residual shunt after PFO closure was associated with an increased incidence of recurrent stroke or TIA: 2.32 versus 0.75 events per 100 patient-years (hazard ratio [HR], 3.05 [95% CI, 1.65 to 5.62]; P < 0.001). This result remained robust after adjustment for important covariates, namely age; study period; device; presence of atrial septal aneurysm, hypertension, hyperlipidemia, diabetes, hypercoagulability, or hypermobile septum; and medication use (HR, 3.01 [CI, 1.59 to 5.69]; P < 0.001). Further stratification based on shunt size revealed that moderate or large residual shunts were associated with a higher risk for stroke or TIA recurrence (HR, 4.50 [CI, 2.20 to 9.20]; P < 0.001); the result for small residual shunts was indeterminate (HR, 2.02 [CI, 0.87 to 4.69]; P = 0.102).
    Nonrandomized study with potential unmeasured confounding.
    Among patients undergoing PFO closure to prevent future stroke, the presence of residual shunt, particularly a moderate or large residual shunt, was associated with an increased risk for stroke or TIA recurrence.
    National Institutes of Health.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Understanding the determinants of persistent smoking after a coronary event constitutes the basis of modelling interventions of smoking cessation in secondary prevention programs. We aim to identify the potentially modifiable medical, sociodemographic and psychosocial factors, comprising the study factors, associated with unfavourable risk factor control after CHD events.
    A cross-sectional explorative study used logistic regression analysis to investigate the association between study factors and smoking status in 1083 patients hospitalized with myocardial infarction and/or coronary revascularization. Hospital record data, a self-report questionnaire, clinical examination and blood samples were applied.
    At the index hospitalization, 390 patients were smoking and at follow-up after 2-36 months 167 (43%) of these had quit, while 230 reported persistent smoking. In adjusted analyses, unemployed or disability benefits (Odds ratio (OR) 4.1), low education (OR 3.5), longer smoking duration (OR 2.3) and not having ST-elevation myocardial infarction (STEMI) as index event (OR 2.3) were significantly associated with persistent smoking. Psychosocial factors at follow-up were not associated with persistent smoking. Smokers reported high motivation for cessation, with 68% wanting help to quit. Only 42% had been offered nicotine replacement therapy or other cessation aids. Smokers rated use of tobacco as the most important cause of their coronary disease (6.8 on a 1-10 Likert scale).
    Low socioeconomic status, prior duration of smoking, and not having STEMI as index event were associated with persisting smoking. Persistent smokers in this study seem to have an acceptable risk perception and were motivated to cease smoking, but needed assistance through cessation programs including prescription of pharmacological aids.
    Registered at ClinicalTrials.gov: NCT02309255 , registered retrospectively.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号